Efficacy of intranasal fluticasone propionate nano nasal spray in management of chronic rhinitis: a randomized clinical trial

Abstract

Common inflammatory conditions of the airways, such as chronic rhinitis, nasal polyposis, and seasonal and chronic allergic rhinitis, can significantly impact the health and quality of life of a patient. Intranasal corticosteroids are recommended as a part of the treatment plan for each of these conditions because they can help reduce symptoms by reducing inflammation. In this randomized, controlled trial, 30 individuals with rhinitis were enrolled to compare the efficacy of a new nano formulation of Fluticasone Propionate nano-nasal spray (FP-NNS) with the commercially available FP-NS nasal spray in the treatment of allergic rhinitis (15 to 60 years). Patients were administered 50 µg doses of FP-NNS in the morning and evening. This regimen was administered as a nasal spray during a 4-week phase evaluating its efficacy and safety. Each efficacy endpoint was analyzed using analysis of variance. More of our clinical studies have demonstrated that FP-NNS decreases inflammatory markers in both adults and children.